RA: One JAK to Rule Them All?

Dr. Brian Jaros reports on abstract 1362, presented at the 2024 ACR Convergence meeting in Washington, DC.

Join The Discussion

eugene fung

| Nov 16, 2024 11:26 pm

Permalink

The article was done by Manufacturer , and the comparison is Upa and "others "
There are thousand of Upa vs Hundred and even 2 perficitinib
The initiation of Moderate activity in Upa 63% others 51%

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×